

I. AMENDMENTS

Please enter the following amendments without prejudice or disclaimer.

In the claims:

Please cancel claims 11, 12, 27 and 28.

In claims 4 and 25, please delete “consist” and insert --consists-- therefor.

In claims 6 and 26, please insert --second-- between “co-administered” and “cells”.

In claim 10, please insert --second-- between “said” and “cells”.

In claim 19, please insert --said-- between “wherein” and “therapeutic” and please delete “,” between “protein” and “or”.

3. (Twice Amended) A method of treating a disease in a mammal wherein said method comprises co-administering of retinal pigmented epithelial (RPE) cells with a second cell population to the mammal, wherein said co-administered second cells [that] supply a therapeutic protein or other biologically active molecule, wherein said RPE cells and said co-administered second cells [that supply a therapeutic protein or other biologically active molecule] are allogeneic [or xenogeneic] to the mammal and wherein said RPE cells are administered in an amount effective to create an immunologically privileged site and said co-administered second cells [that supply a therapeutic protein or other biologically active molecule] are administered in an amount effective to sustain a therapeutic effect.

5. (Amended) The method of Claim 3 wherein said co-administered second cells [that produce said therapeutic molecule] are cells transformed by a nucleic acid encoding said therapeutic protein or other biologically active molecule.

15. (Twice Amended) The method of Claim 3 wherein the RPE cells, or co-administered second cells, [that supply the therapeutic protein or other biologically active molecule] are re-administered in an effective amount to sustain a therapeutic effect.

16. (Twice Amended) A pharmaceutical composition comprising retinal pigmented epithelial (RPE) cells and a second cell population, wherein the second cells [that] produce a therapeutic protein or other biologically active molecule, wherein said RPE cells are allogeneic [or xenogeneic] to the second cells [that produce the therapeutic protein or other biologically active molecule], and a pharmaceutically acceptable carrier.

18. (Twice Amended) A pharmaceutical composition comprising retinal pigmented epithelial (RPE) cells and a second cell population, wherein the second cells [that] produce a therapeutic protein[,] or other biologically active molecule, wherein said RPE cells and the second cells are attached to a matrix[,] and wherein said RPE cells are allogeneic [or xenogeneic] to the second cells [that produce the therapeutic protein, or other biologically active molecule].

21. (Amended) A compartmentalized kit adapted to receive a first container adapted to contain retinal pigmented epithelial (RPE) cells and a second container adapted to contain a second cell population, wherein said RPE cells are allogeneic to the second cells and wherein the second cells [that] produce a therapeutic molecule that is absent or defective in a disease.

22. (Amended) A compartmentalized kit adapted to receive a first container adapted to contain retinal pigmented epithelial (RPE) cells and a second container adapted to contain pancreatic islet of Langerhans cells, wherein said RPE cells are allogeneic to the pancreatic islet of Langerhans cells.